Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En kombination af to i øjeblikket godkendte lægemidler til at forbedre behandlingen af ​​skizofreni

18. juli 2006 opdateret af: Eli Lilly and Company
Undersøgelse af en medicin til behandling af skizofreni hos patienter, der allerede tager Abilify, Risperdal, Seroquel, Zyprexa

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Cerritos, California, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
      • Chula Vista, California, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.
      • Garden Grove, California, Forenede Stater
        • For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
      • San Diego, California, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • Connecticut
      • New Haven, Connecticut, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
      • New Haven, Connecticut, Forenede Stater
        • For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
    • Georgia
      • Atlanta, Georgia, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • Illinois
      • Chicago, Illinois, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • Indiana
      • Indianapolis, Indiana, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • Iowa
      • Iowa City, Iowa, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • New Hampshire
      • Lebanon, New Hampshire, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • New York
      • New York, New York, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • North Carolina
      • Butner, North Carolina, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
      • Chapel Hill, North Carolina, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • Oklahoma
      • Okalahoma City, Oklahoma, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
    • Texas
      • Austin, Texas, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
      • Irvin, Texas, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
      • Irving, Texas, Forenede Stater
        • For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
      • San Antonio, Texas, Forenede Stater
        • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 55 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inklusionskriterier:

  • Skal have en klinisk diagnose skizofreni
  • Skal være mindst 18 år og ikke ældre end 55 år
  • Skal have været stabil på en dosis af Abilify, Risperdal, Seroquel eller Zyprexa i de sidste 8 uger
  • Kvinder i den fødedygtige alder skal bruge en medicinsk accepteret præventionsmiddel
  • Skal kunne sluge kapsler

Ekskluderingskriterier:

  • Har andre alvorlige helbredsproblemer end skizofreni
  • Tager et antidepressivt middel mod depression
  • Tager insulin mod diabetes
  • Har en historie med alkohol- eller stofafhængighed (undtagen nikotin og koffein) inden for de seneste 6 måneder

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Datoer for studieregistrering

Først indsendt

16. august 2004

Først indsendt, der opfyldte QC-kriterier

17. august 2004

Først opslået (Skøn)

18. august 2004

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

20. juli 2006

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. juli 2006

Sidst verificeret

1. juli 2006

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med placebo

Abonner